Tumor Gene Expression in Women With Ovarian Cancer

Completed · Phase 4 · Has a placebo group

Conditions studied: Ovarian Cancer

In brief

The study objective is to compare changes in expression of glucocorticoid-induced genes that may be involved in cell survival signaling in the tumors of ovarian cancer patients before and after an intraoperative dose of 20mg dexamethasone.

Key facts

Study ID

NCT00817479

Run by

University of Chicago

People needed

20

Starts

2003-01-01

Expected to finish

2013-01-01

Last updated by the study team

2016-07-13

Who can join

Age: 18 and older, up to 59. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Subject has intraabdominal disease either proven or strongly suspected to be ovarian or primary peritoneal cancer, and will be undergoing surgical debulking.
• Subject is not allergic to dexamethasone, and there is no obvious medical contraindication to dexamethasone.
• Subjects with diabetes requiring drug therapy are excluded.
• Subject is not currently receiving glucocorticoid therapy
• Nasal steroids (e.g. Flonase) are permitted
• Subject understands that this protocol does not have therapeutic intent
• Preoperative serum albumin at least 3.0 mg/dL
• Negative serum or urine pregnancy test in women of childbearing potential
• Signed informed consent

You may not qualify if…

• Males do not get ovarian cancer and therefore will not be included in this trial.
• Patients of all ethnic backgrounds are eligible and will be encouraged to enroll. However we do not expect differences based on ethnicity, and this small study will not therefore be powered to make conclusions about ethnic differences in induction of GR-regulated genes with dexamethasone.

Where it is running

• The University of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.